Last updated: February 24, 2026
What is the Drug?
NDC 66758-0959 corresponds to Repatha (evolocumab), a monoclonal antibody used to lower low-density lipoprotein (LDL) cholesterol. Repatha is primarily prescribed for homozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
Market Position and Demand
Therapeutic Area and Competition
Repatha operates within a competitive landscape of PCSK9 inhibitors, including Praluent (alirocumab). These drugs target patients with high cardiovascular risk who require intensive LDL reduction. The prevalence of hypercholesterolemia in US adults exceeds 93 million, with roughly 13 million qualifying for PCSK9 inhibitors based on guideline criteria.[1]
Key Market Drivers
- Unmet needs: Patients with familial hypercholesterolemia and those intolerant to statins.
- Guideline updates: Recent guidelines emphasize intensive LDL lowering, expanding eligible patient populations.
- Cardiovascular disease burden: High global incidence sustains demand for effective lipid-lowering therapies.
Market Size and Trends
The global PCSK9 inhibitor market was valued at approximately USD 4.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8-10% through the next five years.[2] The US accounts for the major share, driven by high cardiovascular disease prevalence and widespread insurance coverage.
Current Pricing Structure
Wholesale Acquisition Cost (WAC)
As of 2023, Repatha's average list price is around USD 5,850 per year, roughly USD 488 per month. Actual transaction prices often reflect discounts, rebates, and negotiated prices with payers.
Access and Reimbursement
Repatha is covered by most commercial insurers and Medicaid, with prior authorization typically required. Co-pays for eligible patients range from USD 0 to USD 50 monthly after insurance.
Pricing Compared to Competitors
| Drug |
List Price (Annual USD) |
Administration |
Key Differentiator |
| Repatha |
5,850 |
Subcutaneous |
Higher efficacy in certain hypercholesterolemia populations |
| Praluent |
4,950 |
Subcutaneous |
Slightly lower list price |
| Inclisiran (Leqvio) |
3,600 (per-dose) |
Intramuscular |
Twice-yearly dosing, lower annual cost |
Price Projections
Short-term (1-2 years)
- Stable pricing: No significant reduction expected globally due to manufacturing costs and ongoing R&D investments.
- Rebate adjustments: Insurance negotiations may lead to marginal list price discounts, particularly in competitive markets.
Medium-term (3-5 years)
- Potential price erosion: Likely driven by biosimilar or biobetter entrants, if approved.
- Shift to value-based pricing: Payers may negotiate discounts tied to real-world outcomes.
Long-term (5+ years)
- Market saturation and biosimilar competition could reduce prices by 20-30%. Adoption of biosimilar versions or alternative small-molecule therapies could further compress price points.[3]
Factors Influencing Price Trajectory
- Regulatory changes: Increased pressure to lower drug prices.
- Patent expirations: Repatha's patent estate extends through 2027, with some patents potentially expiring earlier, allowing biosimilar entry.
- Healthcare policies: Cost-control measures and value-based agreements.
Key Market Risks and Opportunities
- Risks: Patent challenges, biosimilar competition, regulatory clampdowns, and payer resistance.
- Opportunities: Expansion into new indications, combination therapies, and personalized medicine approaches.
Summary of Market Outlook
| Aspect |
Outlook |
| Market growth |
8-10% CAGR until 2027 |
| Pricing trend |
Slight decline expected post-2025 in mature markets |
| Competition |
Increasing influence of biosimilars and alternatives |
| Revenue projections |
USD 8-12 billion globally by 2030 |
Key Takeaways
- The product remains a centerpiece in lipid-lowering therapy with stable near-term pricing.
- Market growth driven by expanding indications and cardiovascular burden.
- Long-term price declines driven by biosimilar entry and policy shifts.
- Significant revenue is expected through continued demand among high-risk patient segments.
- Monitoring regulatory and patent developments is essential for strategic positioning.
FAQs
1. How does Repatha’s price compare internationally?
Prices vary by country, often significantly lower outside the US due to government negotiations; in Europe, annual costs can range from USD 3,000 to USD 4,000.
2. What impact could biosimilar competition have?
Entry of biosimilars can reduce Repatha’s price by 20-30% over five years, with potential for wider access.
3. Are there any anticipated patent expirations?
Some key patents are set to expire around 2027, opening the market for biosimilar alternatives.
4. How do payer restrictions affect pricing?
Stringent prior authorization and step therapy limit immediate access but can incentivize discounts and rebates to gain formulary placement.
5. What is the potential for future indications?
Research into broader cardiovascular and metabolic indications could increase market size, but regulatory approval timelines vary.
References
- American Heart Association. (2022). Statistics on cholesterol and cardiovascular disease.
- MarketsandMarkets. (2023). PCSK9 inhibitors market forecast.
- IQVIA. (2022). Global biosimilar market analysis.
[1] American Heart Association. (2022). Statistics on cholesterol and cardiovascular disease.
[2] MarketsandMarkets. (2023). PCSK9 inhibitors market forecast.
[3] IQVIA. (2022). Global biosimilar market analysis.
